SOPHiA Genetics (SOPH) Initiation of Coverage
Key Points
- Revenue growth reaccelerated from +4% in FY2024 to +19% in FY2025, and is guided to +22-24% for FY2026.
- U.S. market has become the primary growth engine, with Q2 2026 U.S. revenue up +64% YoY.
- Liquid biopsy and companion diagnostics (CDx) are emerging as high-growth, high-value product lines.
- Biopharma segment rebounded from headwinds in 2024 to become a growth accelerator in 2026, with new AstraZeneca contracts.
- Gross margins remain strong (adjusted gross margin >72% since FY2023), though some sequential pressure noted in Q2 2026.
- Adjusted EBITDA loss improved materially, with >60% of incremental revenue dropping to the bottom line in Q2 2026.
- Cash position strengthened to $107.7M at end-Q2 2026 after a $57.5M public offering.
Business Overview
SOPHiA GENETICS SA operates a global AI-driven platform for precision medicine, focusing on genomic diagnostics, companion diagnostics, and real-world evidence generation. The company’s decentralized model enables hospitals and labs worldwide to scale their own testing capabilities, leveraging proprietary AI algorithms and a growing network of over 1,000 institutions across 75 countries. Revenue is generated via consumption-based SaaS, bundled kits, and integrated access modes, with business split between clinical diagnostics and biopharma partnerships.
Financial Snapshot: Annual Actuals
Key Financial Metrics (Fiscal Years)
| Fiscal Year | Revenue ($M) | YoY Growth (%) | Platform Analysis Volume | Gross Margin (%) | Adjusted Gross Margin (%) | Adjusted EBITDA Loss ($M) | Cash & Equivalents ($M) |
|---|---|---|---|---|---|---|---|
| 2025 | 77.3 | +19 | 391,000 | 67.4 | 74.2 | -41.5 | 70.3 |
| 2024 | 65.2 | +4 | - | - | 72.8 | -40.2 | 80.2 |
| 2023 | 62.4 | +31 | 317,000 | - | 72.0 | -55.9 | 123.3 |
Notes: Adjusted EBITDA loss is non-IFRS; cash burn excludes FX impacts where noted.
Financial Snapshot: Quarterly Actuals
Key Financial Metrics (Quarterly)
| Quarter | Revenue ($M) | YoY Growth (%) | Platform Analysis Volume | Gross Margin (%) | Adjusted Gross Margin (%) | Adjusted EBITDA Loss ($M) | Cash & Equivalents ($M) | Net Dollar Retention (%) | Core Genomic Customers |
|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 23.3 | +27 | 115,000 | 64.6 | 72.1 | -8.8 | 107.7 | 117 | 542 |
| Q1 2026 | 21.7 | +22 | 108,000 | 68.0 | 75.4 | -9.2 | 65.4 | 117 | 537 |
| Q4 2025 | 21.7 | +22 | 105,000 | 67.7 | 73.9 | -9.9 | 70.3 | 115 | 528 |
| Q3 2025 | 19.5 | +23 | 99,000 | 66.3 | 73.1 | -10.2 | 81.6 | 108 | 488 |
| Q2 2025 | 18.3 | +16 | - | - | 74.4 | -11.7 | 94.8 | - | 490 |
| Q1 2025 | 17.8 | +13 | - | - | 75.7 | -9.8 | 68.5 | - | 490 |
| Q2 2024 | 15.8 | +5 | 87,000 | - | 73.2 | -9.9 | 105.4 | 114 | 457 |
| Q1 2024 | 15.8 | +13 | 84,000 | - | 70.5 | -14.1 | 103.7 | 123 | 463 |
Segment Analysis
Segment Revenue Mix (Q2 2026)
| Segment | Key Products/Services | Growth Drivers |
|---|---|---|
| Clinical Genomics | SOPHiA DDM, HemOnc, Rare Disease, Exome | U.S. expansion, expand engine |
| Liquid Biopsy | MSK-ACCESS, MSK-IMPACT | High ASP, global adoption |
| Biopharma | CDx, AI models, RWE | AZ contracts, new CDx wins |
- U.S. Market: Q2 2026 revenue +64% YoY, volume +60% YoY. Key drivers include enhanced exome product, HemOnc, and increasing demand for in-house testing.
- Liquid Biopsy: Q2 2026 revenue +80% YoY. 80 customers signed globally; >50% not yet generating revenue.
- Biopharma: Two new CDx deals with AstraZeneca in Q2 2026. Segment transitioned from headwind in 2024 to growth accelerator in 2026.
Competitive Position
- SOPHiA GENETICS has built a defensible moat via its global network (>1,000 institutions), proprietary AI platform, and decentralized approach.
- Competes with central labs and send-out labs; unique value proposition in enabling in-house testing and scalable AI analytics.
- Partnerships with leading institutions (MSK, Mount Sinai, AstraZeneca) and expansion into regulated CDx products differentiate the company.
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Accelerating revenue growth (+27% YoY in Q2 2026) | Gross margin declined sequentially in Q2 2026 |
| Strong U.S. market momentum (+64% revenue YoY) | Biopharma margins lower at project start |
| High net dollar retention (117% in Q2 2026) | Implementation backlog remains elevated |
| Successful capital raise ($57.5M, cash $107.7M) | Latin America remains soft, leadership changes |
| Two landmark CDx deals with AstraZeneca | Operating expenses impacted by FX, litigation costs |
| Expand engine driving multi-app adoption | New business ramp timing can be unpredictable |
| Core genomic customers up to 542 in Q2 2026 | BioPharma segment underperformed in 2024 |
| Adjusted gross margin above 72% every year since FY2023 | FX volatility impacting reported results and expenses |
| Major AstraZeneca contract signed (largest ever) | Operating losses remain significant |
| Liquid biopsy revenue +80% YoY in Q2 2026 | BioPharma revenue timing depends on milestones |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Ramp-up of large U.S. health system contracts | Delays in customer implementation/backlog conversion |
| Launch and scaling of CDx programs with AstraZeneca | FX headwinds (Swiss franc, euro vs USD) |
| Expansion of liquid biopsy and MSK-ACCESS customers | Litigation costs (Guardant Health patent suits) |
| Continued improvement in adjusted EBITDA loss | Margin dilution from pharma/services ramp |
| Further adoption of AI-native productivity tools | Slow recovery in Latin America |
| JV with Memorial Sloan Kettering for AI lab | Potential regulatory hurdles for CDx launches |
| Ramp-up of AstraZeneca contract (milestone revenue in 2026) | Delays in BioPharma deal execution or milestone achievement |
| Accelerated implementation of new customers | Prolonged implementation timelines for complex applications |
| Expansion in U.S. market (major new wins: UC Irvine, Mayo Clinic, Mount Sinai) | Sales and marketing expense increases (commission-driven) |
| Enhanced Exome product driving rare disease adoption | Competition in rare disease analytics increasing |
